Novartis Lescol XL
This article was originally published in Pharmaceutical Approvals Monthly
Extended-release 80 mg tablet formulation of fluvastatin produced up to a 38% median decrease in low-density lipoprotein cholesterol in patients with dyslipidemia compared to Lescol 40 mg in Phase III clinical trials, the company said, announcing the Oct. 6 approval of the new tablet. "A 25% median decrease in triglycerides and a 13% mean increase in high-density lipoprotein cholesterol in patients with primary mixed dyslipidemia (Fredrickson Type IIb)" compared to Lescol 40 mg was also seen in the trials, the company reported. The NDA for the extended-release formulation was submitted Dec. 8, 199
You may also be interested in...
If President Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsberg, Affordable Care Act coverage could disappear. See what Kyle Sampson, a partner with the Washington, DC law firm King & Spalding said about it here.
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.